Medication info
Citiril Tablet (Glimepiride)

Citiril Tablet (Glimepiride)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
CTC Bio, Co., Ltd.
Appearance
Green oval-shaped tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201802132 · Approved 2018.05.21 · Insurance code 669502330

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose should be adjusted individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. Take this medicine before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received drug therapy, initiate treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. Generally, there is little additional effect with doses above 4 mg, although some patients have achieved better metabolic control by increasing the dose to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control may improve during treatment, the amount of this medicine required may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered in the event of weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is advisable to follow the instructions given under Initial dose. That is, treatment may be initiated at 1 mg once daily, and the dose adjusted at intervals of 1 ~ 2 weeks. The potency and duration of action of the previous medication should be taken into account. 4) Dose monitoring While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly; regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia can be corrected immediately by consuming sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with a sulfonylurea. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization may sometimes be necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal. Initiate insulin at a low dose and increase it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin dose adjustment at regular intervals is necessary while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If a patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Clinical information has been published on combination therapy with metformin and other sulfonylureas, including glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level can be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia when this medicine is administered with metformin, and the risk may increase. Appropriate precautions should be taken.

Ingredients

Manufacturer
CTC Bio, Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Poor blood sugar control in type 2 diabetes patients
View approved original text

This medication is used to improve blood sugar control in type 2 diabetes patients by supplementing their dietary regimen and exercise. It can be taken alone or, in cases where blood sugar control is insufficient, in combination with oral hypoglycemic agents or insulin. Additionally, in cases where mono therapy with sulfonylureas or metformin is insufficient, it can be combined with metformin to enhance blood sugar control. Thus, this drug supports blood sugar management tailored to various conditions, improving patient health.

How to take

Adult dose

The dose should be adjusted individually for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. Take this medicine before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received drug therapy, initiate treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. Generally, there is little additional effect with doses above 4 mg, although some patients have achieved better metabolic control by increasing the dose to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control may improve during treatment, the amount of this medicine required may decrease. Therefore, dose reduction or discontinuation of this medicine may be necessary to avoid hypoglycemia. Dose adjustment should also be considered in the event of weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is advisable to follow the instructions given under Initial dose. That is, treatment may be initiated at 1 mg once daily, and the dose adjusted at intervals of 1 ~ 2 weeks. The potency and duration of action of the previous medication should be taken into account. 4) Dose monitoring While taking this medicine, blood glucose and/or urine glucose levels should be measured regularly; regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia can be corrected immediately by consuming sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with a sulfonylurea. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization may sometimes be necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal. Initiate insulin at a low dose and increase it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin dose adjustment at regular intervals is necessary while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If a patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Clinical information has been published on combination therapy with metformin and other sulfonylureas, including glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level can be achieved by adjusting the dose of each drug. However, efforts should be made to determine the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia when this medicine is administered with metformin, and the risk may increase. Appropriate precautions should be taken.

Precautions

This medication should not be used in patients with insulin-dependent diabetes or in patients with diabetic ketoacidosis or in a comatose state. Moreover, patients who have had hypersensitivity reactions to this medication or to sulfonylureas or sulfonamide drugs should not be administered this medication. For patients with severe liver or kidney dysfunction, transitioning to insulin therapy is recommended instead of using this medication. Women who are pregnant or may become pregnant, and those who are breastfeeding should also avoid using this medication. In cases of severe infections, pre- and post-surgical conditions, or in patients with severe trauma, insulin therapy is recommended. Patients with gastrointestinal disorders may have impaired food absorption, leading to a risk of hypoglycemia, and should exercise caution. This medication contains lactose, so patients with lactose intolerance or certain genetic metabolic disorders should not take it. During the initial phase of treatment, there is a high risk of hypoglycemia, so careful monitoring of blood sugar is necessary, especially for patients with poor nutritional status, irregular eating habits, the elderly, and those with impaired kidney or liver function. Patients who consume alcohol or have other endocrine disorders may also be at increased risk of hypoglycemia. Furthermore, this medication contains Yellow No. 4 dye, so caution should be exercised by patients allergic to this component. This medication may cause hypoglycemia, which can manifest as symptoms such as headache, severe hunger, nausea, fatigue, confusion, drowsiness, and in severe cases, loss of consciousness. Visual disturbances, gastrointestinal symptoms, liver dysfunction, blood abnormalities, and allergic reactions have also been reported, so if any abnormal symptoms arise, immediate consultation with a physician is required. When taking this medication, dietary and exercise regimens should be followed, and it is crucial to take it regularly. If hypoglycemia occurs, consuming foods containing sugar immediately can alleviate symptoms, and it is advisable to always carry sugar. When taken with other medications, interactions may occur, so all medications being taken should be reported to the healthcare provider. In particular, some antibiotics, antifungals, beta-blockers, and steroids may alter the effectiveness of this medication. Pregnant or breastfeeding women are encouraged to consider insulin therapy instead of this medication due to potential effects on the fetus or newborn. The safety and efficacy of this medication in children under 18 years have not been established, and in the elderly, dosage adjustments may be necessary due to declining kidney function. In the case of overdose, severe hypoglycemia may occur, necessitating immediate hospital treatment, and if symptoms of hypoglycemia are severe, a glucose injection may be required. This medication should be stored out of reach of children and kept securely in its original container.

Side effects

hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disorders, anxiety, aggression, decreased concentration, decreased agility or drive, depression, confusion, speech abnormalities, aphasia, visual impairment, tremors, incomplete paralysis, sensory disturbances, dizziness, weakness, loss of self-control, temporary mental confusion, cerebral convulsions, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and moist skin, tachycardia, hypertension, palpitations, angina, heart arrhythmia, blurred vision, fullness or pressure in the upper abdomen, abdominal pain, diarrhea, elevated liver enzymes, liver dysfunction, bile secretion disorder, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, erythropenia, agranulocytosis, pancytopenia, itching, urticaria, rash, respiratory distress, hypotension, shock, anaphylaxis, angioedema, Stevens-Johnson syndrome, allergic vasculitis, cutaneous photosensitivity reactions, decreased serum sodium concentration, taste disorders, hair loss, weight gain, dizziness, liver dysfunction, abdominal pain, arthralgia, indigestion, facial swelling, erectile dysfunction, facial flushing, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. The recommended storage temperature is room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Green oval-shaped tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.